About the Authors
- José Humberto Tavares Guerreiro Fregnani
-
* E-mail: mdfregnani@terra.com.br
Affiliations Research and Teaching Institute – Barretos Cancer Hospital (IEP – HCB), Barretos, Brazil, National Institute of Science and Technology of the Diseases Associated to the Papillomavirus (INCT-HPV)/Santa Casa de São Paulo Medical School- FCMSCSP), São Paulo, Brazil
- André Lopes Carvalho
-
Affiliation Research and Teaching Institute – Barretos Cancer Hospital (IEP – HCB), Barretos, Brazil
- José Eluf-Neto
-
Affiliations National Institute of Science and Technology of the Diseases Associated to the Papillomavirus (INCT-HPV)/Santa Casa de São Paulo Medical School- FCMSCSP), São Paulo, Brazil, Departament of Preventive Medicine – Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, Brazil
- Karina de Cássia Braga Ribeiro
-
Affiliations National Institute of Science and Technology of the Diseases Associated to the Papillomavirus (INCT-HPV)/Santa Casa de São Paulo Medical School- FCMSCSP), São Paulo, Brazil, Departament of Social Medicine – Santa Casa de São Paulo Medical School (FCMSCSP), São Paulo, Brazil
- Larissa de Melo Kuil
-
Affiliation Research and Teaching Institute – Barretos Cancer Hospital (IEP – HCB), Barretos, Brazil
- Tauana Arcadepani da Silva
-
Affiliation Research and Teaching Institute – Barretos Cancer Hospital (IEP – HCB), Barretos, Brazil
- Silvia Lapola Rodrigues
-
Affiliation Research and Teaching Institute – Barretos Cancer Hospital (IEP – HCB), Barretos, Brazil
- Edmundo Carvalho Mauad
-
Affiliation Research and Teaching Institute – Barretos Cancer Hospital (IEP – HCB), Barretos, Brazil
- Adhemar Longatto-Filho
-
Affiliations Research and Teaching Institute – Barretos Cancer Hospital (IEP – HCB), Barretos, Brazil, National Institute of Science and Technology of the Diseases Associated to the Papillomavirus (INCT-HPV)/Santa Casa de São Paulo Medical School- FCMSCSP), São Paulo, Brazil, Medical Research Laboratory 14– Medicine School of Universidade de São Paulo (USP), São Paulo, Brazil
- Luisa Lina Villa
-
Affiliation National Institute of Science and Technology of the Diseases Associated to the Papillomavirus (INCT-HPV)/Santa Casa de São Paulo Medical School- FCMSCSP), São Paulo, Brazil
Competing Interests
This study was partially supported by Merck & Co., Inc. Merck & Co., Inc. provided the vaccine by Merck Investigator Studies Program (MISP) to the first author (José Humberto Fregnani, on behalf of Barretos Cancer Hospital). Luisa Lina Villa participated in several clinical trials that validated the safety and efficacy of the quadrivalent vaccine and is a member of the study advisory committee of Merck & Co., Inc. She never received any grant from the company to support her research activities. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: JHTGF ALC JEN KdCBR ECM ALF LLV. Performed the experiments: JHTGF LMK TAdS SLR. Analyzed the data: JHTGF LMK TAdS SLR. Wrote the paper: JHTGF ALC JEN ECM ALF LLV.